Solid tumors often resist immunotherapy due to an immunosuppressive tumor microenvironment. Here, the authors develop CancerPAM, a multiomics CRISPR pipeline that enables tumor-specific cytokine expression to boost immune infiltration and CAR T cell efficacy in neuroblastoma.
- Michael Launspach
- Julia Macos
- Annette Künkele
